The presentation will be available on the Rectify website at https://rectifypharma.com/publications/.

In the pivotal, Phase III NUC-5 trial, (NCT03872921), NCA showed statistical superiority over placebo in achieving the ...

Dr Falk Pharma, a research-based pharmaceutical company specialising in digestive and metabolic medicine, has announced ...

Dr. Falk Pharma, a research-based pharmaceutical company specializing in digestive and metabolic medicine, today announced ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is ...

Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab, commented, “This new clinical data further confirms the potential of nebokitug (CM-101) as a first-in-class treatment for primary ...

New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

For more information on the press release, click on the following link : Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant ...

For more information on the press release, click on the following link : Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant ...

1 CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes, T Snir, R Greenman, R Aricha, I Vaknin, M Frankel ...